BioMarin CFO Resigns, Interim Appointed
Ticker: BMRN · Form: 8-K · Filed: Apr 23, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1.25 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: cfo-change, management-transition
Related Tickers: BMRN
TL;DR
BioMarin CFO Brad Hauser is out April 15th, Michael Harris steps in as interim. #CFOchange
AI Summary
On April 9, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Brad Hauser, effective April 15, 2024. The company also announced that Michael Harris, Senior Vice President of Finance, will serve as interim CFO. This transition follows a period of significant growth and strategic initiatives for BioMarin.
Why It Matters
The departure of a CFO can signal shifts in financial strategy or internal confidence, potentially impacting investor sentiment and the company's stock performance.
Risk Assessment
Risk Level: medium — A CFO departure, especially without immediate permanent replacement, can introduce uncertainty regarding financial leadership and strategy.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- Brad Hauser (person) — Outgoing Chief Financial Officer
- Michael Harris (person) — Interim Chief Financial Officer
- April 9, 2024 (date) — Date of earliest event reported
- April 15, 2024 (date) — Effective date of CFO resignation
FAQ
Who is the outgoing Chief Financial Officer of BioMarin Pharmaceutical Inc.?
Brad Hauser is the outgoing Chief Financial Officer of BioMarin Pharmaceutical Inc.
When is Brad Hauser's resignation effective?
Brad Hauser's resignation is effective April 15, 2024.
Who will serve as the interim Chief Financial Officer?
Michael Harris, Senior Vice President of Finance, will serve as the interim Chief Financial Officer.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 9, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 770 Lindaro Street, San Rafael, California, 94901.
Filing Stats: 994 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2024-04-23 16:11:06
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value BMRN The Nasdaq Global Se
- $1.25 million — s request for a fee award not to exceed $1.25 million. The foregoing summary description of
Filing Documents
- d797498d8k.htm (8-K) — 29KB
- d797498dex991.htm (EX-99.1) — 238KB
- g797498g04g04.jpg (GRAPHIC) — 7KB
- g797498g41g41.jpg (GRAPHIC) — 7KB
- 0001193125-24-107015.txt ( ) — 457KB
- bmrn-20240409.xsd (EX-101.SCH) — 3KB
- bmrn-20240409_lab.xml (EX-101.LAB) — 17KB
- bmrn-20240409_pre.xml (EX-101.PRE) — 11KB
- d797498d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Stipulation of Compromise and Settlement, dated March 27, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMARIN PHARMACEUTICAL INC., a Delaware corporation Date: April 23, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer